Tavneos linked to remission in ANCA-associated vasculitis

Tavneos (avacopan) safely and effectively promotes clinical remission in people with newly diagnosed or relapsing ANCA-associated vasculitis (AAV), according to a multicenter, real-world study in the U.S. The remission rates after a year of treatment were higher than those in the Phase 3 ADVOCATE trial (NCT02994927), whose…

Sinonasal symptoms, as assessed with 22-item Sinonasal Outcome Test (SNOT-22), a patient-reported questionnaire, are more severe when ANCA-associated vasculitis (AAV) is active than during remission, a study shows. Sinonasal symptoms are those that affect the nose and the sinuses, that is, the air-filled cavities around the eyes and nose.

I recently hit a huge milestone: Eighteen years had passed since my first symptoms of eosinophilic granulomatosis with polyangiitis (EGPA), a type of ANCA-associated vasculitis, began, and it was the 17th anniversary of my diagnosis. My EGPA has been through many stages of growth: sleep-deprived infancy,…

Patrys’ PAT-DX1 and PAT-DX3, two DNA-targeting antibodies known as deoxymabs, can suppress production of the antimicrobial webs implicated in ANCA-associated vasculitis (AAV) without weakening other immune responses, according to preclinical work. These webs, called neutrophil extracellular traps (NETs), are made up of a scaffold of DNA and enzymes…

Having microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) — the two most common types of ANCA-associated vasculitis (AAV) — better determines patients’ clinical features and outcomes than the type of AAV-driving, self-reactive antibodies they have. That’s according to a study in Spain that showed that GPA was an…

People with the rarest type of ANCA-associated vasculitis (AAV), called eosinophilic granulomatosis with polyangiitis (EGPA), and AAV patients with reduced kidney function are more likely to experience thrombosis (blood clots that disrupt blood flow), according to a single-center study in China. Results also indicated AAV patients with higher…

Undergoing plasma exchange or low-dose glucocorticoid therapy did not affect the risk of relapse in people with ANCA-associated vasculitis (AAV), according to a post-hoc analysis of data from a Phase 3 clinical trial. Post-hoc analyses are those specified and performed after a trial is complete. Antibodies against the proteinase…

High blood creatinine levels and results from kidney biopsies at the time of diagnosis were the best predictors of kidney failure risk in people with ANCA-associated vasculitis (AAV) with severe kidney disease, a study found. Blood creatinine levels, a marker of kidney damage, and kidney biopsy findings also predicted…

ANCA-associated vasculitis (AAV) patients receiving a cumulative dose of at least 935 mg of glucocorticoids over six months are more likely to see clinically meaningful side effects, according to a study using calculations based on the Glucocorticoid Toxicity Index (GTI). The findings suggest the GTI, which considers the frequency…

Recruitment is continuing in three countries for a Phase 1b/2a clinical trial testing Alpine Immune Sciences’ povetacicept in adults with autoimmune conditions affecting the kidneys, including ANCA-associated vasculitis (AAV). Called RUBY-3 (NCT05732402), the early study is designed to enroll an estimated 56 patients, ages 18 and older,…